
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow Inc. has demonstrated strong growth potential, with VEVYE revenue increasing 22% quarter-over-quarter to $22.6 million in the third quarter of 2025, alongside a notable 10.5% market share in the national dry eye disease sector. The company’s VEVYE Access for All program is successfully enhancing patient accessibility and driving demand, with an anticipated strengthening of VEVYE's positioning due to upcoming real-world evidence showcasing significant clinical improvements. With projections to achieve a quarterly revenue of $250 million by the fourth quarter of 2027, supported by new product launches and improved insurance coverage, Harrow Inc.'s stock outlook remains positive as it capitalizes on growth opportunities in the ophthalmic market.
Bears say
Harrow Inc. has revised its FY26 revenue expectations down to $352 million from $459 million, primarily due to a worse-than-anticipated sequential decline in first-quarter revenue, contributing to a year-to-date equity weakness of -30%. Additionally, the company’s EBITDA projection of $76 million falls below the previously established guidance range of $80 million to $100 million, reflecting conservative assumptions regarding first-half revenue performance. Concerns over clinical development outcomes, regulatory approvals for pipeline products, and potential dilution risks further compound the negative outlook, suggesting that if product adoption fails to materialize as expected, the company's valuation could be significantly impacted.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares